Chang AE - Search Results

1

Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.

Li Q, Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE. Li Q, et al. Among authors: chang ae. J Immunol. 2005 Aug 1;175(3):1424-32. doi: 10.4049/jimmunol.175.3.1424. J Immunol. 2005. PMID: 16034078

2

Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.

Li Q, Carr A, Ito F, Teitz-Tennenbaum S, Chang AE. Li Q, et al. Among authors: chang ae. Cancer Res. 2003 May 15;63(10):2546-52. Cancer Res. 2003. PMID: 12750278

3

Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.

Ito F, Carr A, Svensson H, Yu J, Chang AE, Li Q. Ito F, et al. Among authors: chang ae. J Immunother. 2003 May-Jun;26(3):222-33. doi: 10.1097/00002371-200305000-00006. J Immunother. 2003. PMID: 12806276

4

Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.

Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE. Li Q, et al. Among authors: chang ae. Cancer Res. 2005 Feb 1;65(3):1063-70. Cancer Res. 2005. PMID: 15705908

5

In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.

Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE. Li Q, et al. Among authors: chang ae. J Immunol. 2009 Sep 1;183(5):3195-203. doi: 10.4049/jimmunol.0803773. Epub 2009 Aug 10. J Immunol. 2009. PMID: 19667089 Free PMC article.

6

Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.

Li Q, Yu B, Grover AC, Zeng X, Chang AE. Li Q, et al. Among authors: chang ae. J Immunother. 2002 Jul-Aug;25(4):304-13. doi: 10.1097/00002371-200207000-00002. J Immunother. 2002. PMID: 12142553

7

Tumor-specific responses in lymph nodes draining murine sarcomas are concentrated in cells expressing P-selectin binding sites.

Tanigawa K, Takeshita N, Craig RA, Phillips K, Knibbs RN, Chang AE, Stoolman LM. Tanigawa K, et al. Among authors: chang ae. J Immunol. 2001 Sep 15;167(6):3089-98. doi: 10.4049/jimmunol.167.6.3089. J Immunol. 2001. PMID: 11544293

8

Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines.

Tanigawa K, Takeshita N, Eickhoff GA, Shimizu K, Chang AE. Tanigawa K, et al. Among authors: chang ae. J Immunother. 2001 Nov-Dec;24(6):493-501. doi: 10.1097/00002371-200111000-00006. J Immunother. 2001. PMID: 11759072

9

A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ. Chang AE, et al. Clin Cancer Res. 2002 Apr;8(4):1021-32. Clin Cancer Res. 2002. PMID: 11948109 Clinical Trial.

10

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.

Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Chang AE, et al. J Clin Oncol. 2003 Mar 1;21(5):884-90. doi: 10.1200/JCO.2003.08.023. J Clin Oncol. 2003. PMID: 12610189 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

346 results

Search Page

Filters